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Abstract
Background: Transplantation is often the only way to treat a number of diseases
leading to organ failure. To overcome rejection towards the transplanted organ (graft),
immunosuppression therapies are used, which have considerable side-effects and
expose patients to opportunistic infections. The development of a model to
complement the physician’s experience in specifying therapeutic regimens is therefore
desirable. The present work proposes an Ordinary Differential Equations model
accounting for immune cell proliferation in response to the sudden entry of graft
antigens, through different activation mechanisms. The model considers the effect of a
single immunosuppressive medication (e.g. cyclosporine), subject to first-order linear
kinetics and acting by modifying, in a saturable concentration-dependent fashion, the
proliferation coefficient. The latter has been determined experimentally. All other
model parameter values have been set so as to reproduce reported state variable
time-courses, and to maintain consistency with one another and with the
experimentally derived proliferation coefficient.
Results: The proposed model substantially simplifies the chain of events potentially
leading to organ rejection. It is however able to simulate quantitatively the time course
of graft-related antigen and competent immunoreactive cell populations, showing the
long-term alternative outcomes of rejection, tolerance or tolerance at a reduced
functional tissue mass. In particular, the model shows that it may be difficult to attain
tolerance at full tissue mass with acceptably low doses of a single immunosuppressant,
in accord with clinical experience.
Conclusions: The introduced model is mathematically consistent with known
physiology and can reproduce variations in immune status and allograft survival after
transplantation. The model can be adapted to represent different therapeutic schemes
and may offer useful indications for the optimization of therapy protocols in the
transplanted patient.
Background
It is unfortunately not rare in medical practice that some diseases lead to organ failure,
which may eventually require organ transplantation. The liver, the kidney and the heart
are the most frequently transplanted organs. Diseases leading to organ transplantation
span a wide spectrum of medical conditions: cancer, infections, autoimmune and degen-
erative diseases. Transplantation into the recipient of a foreign organ (graft), even from an
individual of the same species (allograft), if left to itself causes rejection, a strong response
by the recipient’s immune system leading to irreversible damage of the graft. Depending
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on the time-frame over which rejection occurs, “acute” rejections are differentiated from
“chronic” ones. Acute rejection develops in the first few weeks or months after transplan-
tation and is produced by cellular and molecular mechanisms, which may partially differ
from those leading, over the course of many months or years, to chronic rejection.
After many decades of experimentation on animals and cells, and of the development
of pharmacological tools, organ transplantation has evolved into a common therapeu-
tic procedure. The success of a solid organ transplant relies in equal measure on the
technical aspects of the implant and on the recipient’s acceptance or tolerance of the
implanted graft. This last phenomenon is clinically induced by the administration of
immunosuppressive drugs, which specifically decrease the recipient’s reactivity towards
the graft, thus allowing the maintenance of the functional activity of the organ. Currently
available drugs belong to several classes (calcineurine inhibitors (CNI), antimetabolites,
target of rapamycin (TOR) inhibitors, steroids, and monoclonal antibodies) [1]. Canoni-
cal combinations of these drugs are typically used by the attending physician in a rather
standardized fashion, attempting to maintain measurable drug plasma concentrations
within established limits. Episodic and emergency use of immunosuppressive agents is
then performed if signs of rejection become clinically evident.
Acute rejection response has been extensively studied in vivo and in vitro. From avail-
able studies, indications on the action of several drugs in controlling acute rejection and
maintaining vitality of the graft have been obtained. However, even if the recipient initially
accepts the graft, the more insidious and slow phenomenon of chronic rejection often
ensues. The pathogenesis of chronic rejection is less well known and may depend not
only on a partially different set of immune response mechanisms, but also on actual drug
toxicity, recommending the use of the minimal clinically effective dose of medication.
Rejection has been widely described from a medical and biological viewpoint, but there
have so far been no mathematical models describing this process. Mathematical mod-
els have been used to describe immunological behavior for a long time, beginning with
the classical SIR model (Susceptible-Infectious-Recovered) first created for investigat-
ing the progress of an epidemic [2]. Several models describing the immune response in
a number of diseases exist (HIV infection, tuberculosis, tumors...) [3-7] but, at present,
only one model representing immune system dynamics during transplantation [8] has
been published, which has the important aim to investigate T-cell population growth
mechanisms, using thymus transplantation to follow the development of T-cells and their
regulatory signals. The goal of the present work is somewhat different, in that we attempt
to describe the main features of the immune system dynamics during general solid organ
rejection. This will allow in the future the description of possible consequences of dif-
ferent therapeutic regimens. From the immunologic viewpoint, rejection mechanisms
are substantially different from other immune responses (e.g. towards HIV, tuberculo-
sis, or tumors), and the development of a specific model seems therefore warranted.
Such a model should help transplantation clinicians and allied health care personnel
in forecasting and treating rejection, without relying solely on empirical protocols. A
good mathematical model should eventually allow the physician to consider in real time
the several interrelated aspects of the immune response to transplantation, while jointly
incorporating the known pharmacokinetics of themany potentially useful available drugs.
The ultimate goal would be to help bridge the gap between the pharmacology and the biol-
ogy of transplantation, explaining or at least representing the temporal relations between
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drug efficacy, possible drug adverse effects and the development of immune tolerance or
graft acceptance.
In the present work we propose a tentative mathematical model of the rejection towards
a solid organ transplant (kidney, liver, pancreas, heart). This model describes the evolu-
tion of the main cellular immune response as well as the kinetics and action of a single
representative drug (e.g. cyclosporine). In order to have some physiological support for
parameter assessment, a Mixed Lymphocyte Reaction (MLR) experiment was performed,
on the basis of which the clonal expansion rate of T-cells could be determined. This
experiment was chosen because the parameter of interest for the model was directly
computable from the experimental data. Simulations with Matlab©2010b have been per-
formed and, on the basis of the experimentally determined clonal expansion rate and of
relevant published material, the other model parameters were calibrated. While the cur-
rent model is relatively simple, it introduces the main elements needed for the eventual
description of more detailed response dynamics. Three case scenarios are discussed: non-
immunosuppressed transplantation and two immunosuppressive therapeutical regimens,
one with moderate drug dose and the other with high drug dose. Additional simulations
were made in order to explore different hypothetical therapy scenarios. Also, three state
variables were selected as being most clinically relevant, and a sensitivity analysis was
performed on these at two time points (one and ten years post-transplant).
Methods
Relevant physiology
After transplantation, the majority of exogenous molecules on the allograft are recog-
nized by the immune system as self-antigens, as they are the same in both the donor
and recipient. The main donor molecules which induce the immune response are those
coded from the Major Histocompatibility Complex (MHC) genomic locus, which is the
most polymorphic one on the human genome (it is essentially impossible to find two per-
sons with the same gene cluster, except for monozygotic twins). Proteins coded by the
MHC are located on the cell surface and bind antigen epitopes, creating a complex, which
is recognized by the T-Cell Receptor (TCR) on T-lymphocytes, inducing the immune
response. Cells which carry the MHC/epitope complexes are called Antigen Presenting
Cells (APCs) [9].
In the conventional immune response, self-APCs carry external antigen epitopes
bound to self-MHC molecules. APCs normally circulate in the body and are found in
every organ - during transplantation many APCs from the donor are introduced in the
recipient, and they carry the donor’s MHCs. In fact, MHCs on donor cells are the major
target of the rejection immune response [10], as T-cells can recognize complexes formed
by allogenic MHCs [11]. This mechanism is called “direct activation”, since there is no
processing of the antigen, and it is faster than the indirect activation, where recipient’s
APCs have to process donor’s antigen [12]. In Figure 1 a schematic representation of the
direct and indirect mechanisms is shown.
Every different MHC on the surface of an APC can be recognized by and activate a
different T-cell clone to proliferate (“clonal expansion”). It should be noticed that in the
indirect mechanism many of the foreign epitopes involved are donor MHC fragments,
due to the above mentioned polymorphism [13]. However, indirect activation can also
occur in response to peptides derived from other molecules present in the allograft.
Gaetano et al. Theoretical Biology andMedical Modelling 2012, 9:18 Page 4 of 30
http://www.tbiomed.com/content/9/1/18
donor’s APC 
recipient’s APC 
T-cell 
T-cell 
T-cell 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
T-cell 
clone 
Cascade of 
events leading to 
organ rejection 
D i r e c t  a c t i v a t i o n 
Self MHC 
I n d i r e c t  a c t i v a t i o n 
Self MHC 
Non-self MHC TCR
TCR
TCR
 
Epitope from 
donor’s non-self 
MHC 
Epitope from 
any antigen 
Epitope from non-self 
donor’s molecules 
C l o n a l  e x p a n s i o n 
Figure 1 Direct and indirect activation mechanisms.With the direct activation mechanism the donor’s
Antigen Presenting Cell, expressing its MHC molecule (red) and carrying a general epitope (green), is
recognized from the T-Cell Receptor and activates T-cell clonal expansion. In this case it is the actual MHC
molecule which is recognized as non-self from the TCR. In the lower part of the figure, the two possible
indirect activation scenarios: self APC, expressing self MHCs, can present an epitope from graft antigens
recognized as non-self (blue) or from donor’s MHC (red).
“Alloreactive T-lymphocytes are [in any case] requisite mediators of allograft rejection”
[11].
At the level of detail used in the present work, CD4+ and CD8+ T-lymphocytes
(“helper” and “cytotoxic”) are not distinguished, and we consider them together as T-cells
mediating rejection. The reasons for this simplification are that both T-cell types increase
in number during the immune response and that they can both be activated by exogenous
antigens. It has recently been shown that both class I and II MHCmolecules (respectively
recognized by CD4+ and CD8+ T-cells) can bind extracellular antigens (“cross priming”),
while it was previously thought that class I MHCs could only present intracellular anti-
gen [14]. In the course of direct activation, APCs are either destroyed or will eventually
undergo apoptosis. Since donor’s APCs do not reproduce in the allograft, direct T-cell
activation is a time-limited process. The immune response, however, does not terminate
since there is continuous supply of donor-specific molecules, produced from the con-
stantly proliferating cells in the graft. T-lymphocyte activation occurs as long as the graft
is present in the recipient.
We can thus appreciate two main phases of the immune response to the graft: an initial
strong response, sustained by the activation of T-cells due to a large but fading quantity
of donor APCs, necessitating aggressive immune suppression therapy; and a later, more
or less constant indirect activation of T-cells, sustained by continuously produced graft
epitopes, for which less aggressive therapy is sufficient. It has in fact been reported that
Gaetano et al. Theoretical Biology andMedical Modelling 2012, 9:18 Page 5 of 30
http://www.tbiomed.com/content/9/1/18
the number of directly activated T-cells is larger than the number of indirectly-activated
T-cells, the latter constituting less than 10 percent of the total cellular alloimmune
repertoire [15].
Two aspects of graft rejection have not been explicitly included in the model for sim-
plicity. The first is the increased production of lymphocytes from lymphoid organs,
which receive various signals from stimulating molecules (cytokines). This mechanism
has been shown [16] to take place when an inflammatory process (i.e. rejection) is ongo-
ing. The second aspect of rejection is the appearance of the graft-versus-host disease,
where donor’s T-cells present in the allograft react towards recipient’s antigens. This last
phenomenon depends on the type of the transplanted organ and may be negligible in
most cases of solid organ transplantation.
MLR is an in vitro experiment used to study alloreactive T-cells response to exoge-
nous MHC molecules: it is used in clinical practice as a prediction rejection test before
performing organ transplantation. MLR is induced growing mononuclear cells of an
individual with those of another individual, these cells being isolated from periph-
eral blood: the difference between MHC loci of the two individuals induces clonal
expansion of alloreactive lymphocytes [17]. One of the model parameters, the one
corresponding to the clonal expansion rate of T-cells, was determined by an MLR
experiment.
In the present model we consider one of the most frequently used immunosuppression
therapy protocols, based on calcineurine inhibitors (e.g. cyclosporine)[1], which block
T-cell clonal expansion. Drugs of this class inhibit signal transduction when TCRs rec-
ognize the epitope, so that the cell does not proliferate even when activated. Other types
of therapy, acting through different mechanisms, could also be considered, extending the
present approach.
Themodel
The model is represented in block diagram form in Figure 2, showing all compartments
and the relative dynamics. Organ transplantation is assumed to occur at time tτ in the
life of the patient. Before transplantation, the major components of the immune system
involved in transplant rejection are assumed to be at equilibrium. The choice of the time
t0, at which simulations begin, is therefore irrelevant, as long as t0 < tτ . In order to
represent organ damage, we assume that antigen is released into the blood stream propor-
tionally with the viable mass of the corresponding tissue, and consequently that the viable
graft mass is proportional to bloodstream antigen mass, so that a substantial decrease in
antigen concentration will indicate organ failure.
With the transplantation of an allograft at time t = tτ , the state of the immune system
is suddenly and dramatically altered. The entry of a large amount of already processed
foreign antigen, and the continuous production of foreign antigen by the functional graft
tissue, induce a strong response by the host’s immune system. If this response is not con-
trolled by immunosuppression, rejection and loss of the organ follow. Depending on the
time and mechanisms needed to activate the immune response and on the duration of
antigen permanence in the body, we describe different antigen types and assume that
a specific T-cell type corresponds to each antigen type. In our model we use nonlinear
ordinary differential equations to describe antigen and T-cell dynamics, using appropri-
ate coefficients to specify the effect of antigens on corresponding T-cells and viceversa.
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Figure 2 Model block diagram. State variables are represented with circles, the above ones for the different
antigen types, the bottom ones for specific T-cells. On the bottom right the pharmaceutical dynamics is
represented, the symbol § indicates the site of action of the drug. Solid arrows represent mass transfers, while
dashed lines indicate stimulation and inhibition (arrow end and dot end, respectively).
State variables are generally defined in terms of concentrations, and we suppose a single
vast plasma/interstitial fluid volume space where, given time, all species distribute. State
variables and parameters, with corresponding units of measurement, are listed in Tables 1
and 2, respectively.
E is a generic environmental antigen: we suppose that the individual is constantly
exposed to bacteria, viruses etc. and that the immune system is continuously stimulated
by the corresponding exogenous antigens.When the allograft is transplanted in the recipi-
ent’s body, however, different antigen types are introduced. S represents antigen produced
by graft cells: while these cells reproduce, this antigen is continuously formed. This anti-
gen necessitates processing by endogenous APCs and presentation to T-cells. S in fact
represents the non-processed form, while L is the processed form of the same antigen.
The distinction between the processed and the non-processed forms explains the delay
in processed antigen effect with respect to the directly presented antigen. U indicates
alloantigen directly presented by donor’s APCs, which does not form anew in the organ.
This antigen is ready to be presented to T-cells, so its effect in activating T-lymphocytes is
rapid and strong, but vanishes as APCs are progressively cleared from the organ. Alloanti-
gens which are indirectly presented and which derive from cells not reproducing in the
allograft, have to be processed by endogenous APCs. As it was discussed in the previous
section, this type of antigen does not re-form in the recipient once it is eliminated: Y rep-
resents the non-processed form, while Z represents its processed form, ready to activate
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Table 1Model variables
Variables Units Description
t years time
E μg/l generic antigen (antigenically active molecules): complexes
MHC-antigenic epitopes
S μg/l antigen allograft cells, which reproduce in time, non-processed
form(indirect presentation)
L μg/l antigen allograft cells, which reproduce in time, processed form
(indirect presentation)
U μg/l antigen from APCs in the allograft, not reproducing in it
(direct presentation)
Y μg/l antigen from APCs in the allograft, not reproducing in it, non-processed
form (indirect presentation)
Z μg/l antigen from APCs in the allograft, not reproducing in it,
processed form (indirect presentation)
Ce cell/μl × 103 antigen E specific T-lymphocytes
Cl cell/μl × 103 antigen L specific T-lymphocytes
Cu cell/μl × 103 antigen U specific T-lymphocytes
Cz cell/μl × 103 antigen Z specific T-lymphocytes
F ng/ml cyclosporine
kcac(F) l/μg/year T-cells production rate (T-cells clonal expansion), antigen
and lymphocyte dependent, as function of F
ksτ μg/l S entry rate at time tτ (from reproducing cells, to be processed)
kuτ μg/l U entry rate at time tτ (from non-reproducing cells, directly presented)
kyτ μg/l Y entry rate at time tτ (from non-reproducing cells, to be processed)
T-cells. The processing mechanism is represented in the same way as for antigens S and
L. The model is detailed in the following equations:
dE
dt = ke − kxecCeE − kxeE, E(0) = E0 (1)
dCe
dt = kc + kcac(F)CeE − kxceECe − kxcCe, Ce(0) = Ce0 (2)
dS
dt = ksτ + ksS
(
1 − SS∗
)
− kxscClS, S(0) = 0 (3)
dL
dt = klsS − kxlcClL − kxlL, L(0) = L0 (4)
dCl
dt = kc + kcac(F)ClL − kxcsSCl
− kxclLCl − kxcCl, Cl(0) = Cl0 (5)
dU
dt = kuτ − kxucCuU − kxuU , U(0) = U0 (6)
dCu
dt = kc + kcac(F)CuU − kxcuUCu − kxcCu, Cu(0) = Cu0 (7)
dY
dt = kyτ − kxycCzY − kxyY , Y (0) = Y0 (8)
dZ
dt = kzyY − kxzcCzZ − kxzZ, Z(0) = Z0 (9)
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Table 2Model parameters
Paramaters Value Units Description
t0 35 years minimum time considered by system, in days
tτ 40 years time in which transplantation occurs, in days
ke 1 μg/l/year constant environment antigen entry into the body
kxec 1.5 μl/cell/year × 10−3 second order C dependent E elimination rate constant
kxsc 0.15 μl/cell/year × 10−3 second order C dependent S elimination rate constant
kxlc 0.7 μl/cell/year × 10−3 second order C dependent L elimination rate constant
kxuc 0.5 μl/cell/year × 10−3 second order C dependent U elimination rate constant
kxyc 0.5 μl/cell/year × 10−3 second order C dependent Y elimination rate constant
kxzc 1 μl/cell/year × 10−3 second order C dependent Z elimination rate constant
kxe 1 year−1 first order elimination rate from compartment E
kxl 0.7 year−1 first order elimination rate from compartment L
kxu 0.001 year−1 first order elimination rate from compartment U
kxy 0.001 year−1 first order elimination rate from compartment Y
kxz 1 year−1 first order elimination rate from compartment Z
kls 1.5 year−1 first order transfer rate from compartment S to L
kzy 6 year−1 first order transfer rate from compartment Y to Z
kxc 1 year−1 first order elimination rate from compartment C
kxce 1 l/μg/year second order E dependent Ce elimination rate constant
kxcs 0.02 l/μg/year second order S dependent Cl elimination rate constant
kxcl 0.02 l/μg/year second order L dependent Cl elimination rate constant
kxcu 0.02 l/μg/year second order U dependent Cu elimination rate constant
kxcy 0.02 l/μg/year second order Y dependent Cz elimination rate constant
kxcz 0.02 l/μg/year second order Z dependent Cz elimination rate constant
kc 0.3 cell/μl/year × 103 basal lymphocyte production
ks 2 1/year first order S dependent S production and elimination rate
constant
S∗ 7 μg/l allograft maximum regeneration rate
κ f 0 ng/ml/year drug delivery rate - scenario 1 (no drug treatment)
κ f 36500 ng/ml/year drug delivery rate - scenario 2 (moderate drug treatment)
κ f 127750 ng/ml/year drug delivery rate - scenario 3 (high drug treatment)
kxf 365 1/year first order elimination rate from compartment F
kcacF 2.92 l/μg/year T-cells production rate (T-cells clonal expansion), A and c
dependent
Sτ 1000 μg/l antigen S concentration at time tτ
Uτ 1000 μg/l antigen U concentration at time tτ
Yτ 1000 μg/l antigen Y concentration at time tτ
λ 0.01 ml/ng kcac decreasing coefficient, F dependent
E0 1.38 μg/l E initial condition
S0 0 μg/l S initial condition
L0 0 μg/l L initial condition
U0 0 μg/l U initial condition
Y0 0 μg/l Y initial condition
Z0 0 μg/l Z initial condition
F0 0 ng/ml F initial condition
Ce0 1.1 cell/μl × 103 CE value at t = t0
Cl0 0.3 cell/μl × 103 CL value at t = t0
Cu0 0.3 cell/μl × 103 CU value at t = t0
Cz0 0.3 cell/μl × 103 CZ value at t = t0
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dCz
dt = kc + kcac(F)CzZ − kxcyYCz
− kxczZCz − kxcCz, Cz(0) = Cz0 (10)
dF
dt = kf − kxf F +
κf
kxf
δ(t − tτ ), F(0) = 0 (11)
ksτ = δ(t − tτ )Sτ (12)
kuτ = δ(t − tτ )Uτ (13)
kyτ = δ(t − tτ )Yτ (14)
kf =
{
0, if t ≤ tτ
κf , if t > tτ
(15)
kcac(F) = kcacFe−λF (16)
In equation 1, describing antigen E dynamics, the rate ke represents the entry of
environmental antigens into the body, assumed to be constant throughout the con-
sidered period of time (before as well as after transplantation). The elimination terms
kxec and kxe describe antigen neutralization due respectively to T-cell action and to T-
cell-independent elimination of the antigen (as it happens e.g. through chemical and
physical elimination mechanisms, such as lipases, mucus secreted by respiratory and
gastrointestinal tracts etc.).
Equation 2 represents the dynamics of T-lymphocytes which react towards antigen
E: kc indicates constant physiological T-lymphocyte production from lymphoid organs,
kcac(F)ECe represents T-cell clonal expansion after antigen contact, which is inhibited
by drug action, by setting the rate kcacF as a proper function of the drug concentration
F. T-lymphocytes are also “consumed” by antigen, in the sense that upon T-cell inter-
action with antigen, the lymphocyte eventually undergoes apoptosis (programmed cell
death): this is described by the elimination term kxceECe. We introduced another elim-
ination term, kxcCe: lymphocytes die for apoptosis even if they do not encounter any
antigen after a certain period, and we assume this mechanism to be proportional to T-cell
concentration.
The regenerating antigen is described by equation 3: at time tτ there is an impulsive
entry, modeled by a Dirac delta (Eq. 12). Once the organ is transplanted, its cells regener-
ate: the growth rate is assumed to be logistic of parameter ks, limited by a carrying capacity
S∗, so that S concentration tends towards S∗, whether it is above or below it. The elimina-
tion term kxscClS, depends on S concentration and on T-cells primed from the processed
form of the antigen. The non-processed form is not ready to activate T-lymphocytes, but
it is destroyed by T-cells activated from the processed form. In fact, T-cells activated from
the processed antigen (Cl) are primed to react against cells carrying the same epitopes
(graft cells). Organ rejection is thus represented by the S antigen elimination, this being
related to organ mass.
The processed form of the regenerating antigen is described by equation 4, where the
only positive entry is represented by the term klsS depending on the unprocessed antigen
concentration; the two elimination terms are similar to those in the previous described
equations, representing lymphocyte-dependent and -independent elimination, respec-
tively. Equation 5 describes the Cl lymphocyte dynamics, with the constant entry, the
clonal expansion depending on the processed antigen L, elimination upon encounter
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with both antigens S and L, and antigen-independent elimination. The directly pre-
sented antigen U is represented by equation 6: a Dirac’s delta describes impulsive entry
at transplantation time, while elimination happens in two ways, dependent and inde-
pendent from T-cells, respectively. U-specific T-lymphocytes, Cu, are represented in
equation 7, including constant production rate, clonal expansion, antigen-dependent and
independent elimination.
The last three equations represent the non-regenerating antigen which has to be pro-
cessed, its non-processed form (Y ), the processed form (Z) and Z-specific T-cells. The
dynamics are similar to the S, L and Cl subsystem, the only difference being that this anti-
gen does not regenerate. Equation 8 has an impulsive entry and elimination dependent
and independent from T-lymphocytes; in equation 9 the entry depends on Y concentra-
tion, and the usual two elimination terms follow; equation 10 is similar to equation 5.
Equations 12, 13 and 14 describe the impulsive antigen entries into the system. In each
case an antigen concentration (respectively Sτ , Uτ and Yτ ) is multiplied by a Dirac
delta term acting at time tτ . The end result is the representation of the appropriate
instantaneous change in S, U and Y compartments at the time of transplantation.
Finally, immunosuppressor pharmacokinetics is described by equation 11. For the pur-
pose of the present model, given the long time-scale considered, drug administration is
assumed to be continuous, with average rate kf (equation 15) of delivery into the circu-
lation. The drug is eliminated from the circulation following a linear, first-order process
with rate constant kxf . Since before transplantation no treatment is administered, kf is 0
before time tτ , while it is equal to κf from the time at which therapy begins, which we
assume to be tτ . The term
κf
kxf δ(t − tτ ) represents therefore the (impulsive) loading dose
of the drug, necessary to bring it instantaneously to the equilibrium level, at which it is
constant thereafter. After antigen contact, T-cells would spontaneously give rise to a (fast)
clonal expansion. The immunosuppressive effect of the drug, leading to a slower increase
of T-lymphocyte concentrations, is described by the exponential decrease in the clonal
expansion coefficient kcacF produced by proportionally increasing drug concentrations F
(with effect rate constant λ): this is represented by equation 16. The drug is in fact thought
to block signal transduction after antigen contact, in a concentration-dependent fashion,
thus disabling clonal expansion and reducing T-cell proliferation. Equation 11 represents
the pharmacokinetics of the anti-rejection drug F with given constant entry (depending
on the administration scheme), linear elimination and with impulsive entry assumed to be
simultaneous with transplantation. Equations 12-16 and Tables 1 and 2 define each sym-
bol used. Tables 1 and 2 also report units of measurement for all variables and parameters.
Model parameters
The model has not been fitted to experimental data, although an MLR experiment has
been performed to assess the maximal lymphocyte clonal expansion rate and compute
the parameter kcacF . Indicative parameter values for the processes modelled are difficult
to find in the literature. For this reason, the main criterion followed for parameter cal-
ibration (other than kcacF ) was the production of relative time-courses of the relevant
state variables, which appeared consistent with physiology and clinical experience to the
medical doctors among the authors, while remaining within a broadly acceptable range
of magnitude. For instance, kxc was set at 1/year, whereas values around 0.1/year can be
computed indirectly from normal lymphocyte apoptosis results in vitro [18].
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Mixed lymphocyte reaction
Blood samples were collected from four healthy donors and peripheral blood mononu-
clear cells (PBMCs), from three of the blood samples, were stained with the lipophilic
fluorescent molecule Carboxyfluorescein Succinimidyl ester CFSE. The CellTrace CFSE
Cell Proliferation Kit (Invitrogen) was used following the protocol provided by the man-
ufacturer. Cells were stained with PBS/5%FCS/CFSE-50 μM for ten minutes at room
temperature and then washed twice. Non-labeled PBMCs obtained from the fourth
healthy donor were used as allogenic stimuli and labeled PBMC were cultured in vitro
in the presence or absence of non-labeled PBMC with a ratio of 2:1 (2 × 107 labeled
PBMC versus 107 non-labeled PBMC). Three days later, cells were harvested and stained
with PE-conjugated anti-CD3 mAb (Becton Dickinson). Cells were then analyzed at
cytofluorimeter FACS-calibur (Becton Dickinson) and data were acquired by the software
CellQuest pro.
Parameter computation
Since lymphocytes were exposed to a large amount of allogenic cells, we assume that the
experiment reflects the maximal clonal expansion that can be achieved at a “maximal”
antigen concentration. From equations 2, 5, 7 and 10, kcacF dimensions are l/μg/year.
From the experiment we measured the percentage of replicating cells per day, which has
to be divided by the maximal antigen concentration expressed as μg/l. The concentra-
tion of MHC molecules in the experimental preparation was approximated as follows.
On a cell surface there are approximately 105 MHC molecules, and there were approx-
imately 106 cells/ml of blood. It thus follows that the concentration of MHC molecules
was 105 × 106/ml, i.e. 1014 molecules per liter. Considering both MHC class I and class
II molecules, the average molecular weight is approximately 60 kDa, meaning that one
mole of MHC weights 60 × 103 grams. Since in one mole there is one Number of Avo-
gadro ofmolecules, 1014 molecules correspond to 1014/(6×1023)moles, or approximately
(1018 × 6)/(1023 × 6)) g/l. The parameter kcacF has therefore been computed as the
clonal expansion per day divided by the maximal antigen concentration (10−5 g/l or
10 μg/l), afterwards multiplied by 365 days. No formal statistical parameter estimation
(e.g. Maximum Likelihood-based) was attempted. In keeping with the generally qualita-
tive character of this model’s predictions, the desired outcome of the MLR experiment
was an indicative, plausible value for the rate of clonal expansion, and, as is apparent, this
plausible value itself is conditional on ad-hoc assumptions (e.g. that maximal stimulation
is equivalent to an antigen concentration of 10 μg/l).
Results
Clonal expansion rate fromMLR
In Figure 3 a picture from the cytofluorimetric analysis is shown. Cells labeled with anti-
CD3+ are T-lymphocytes, and those who have replicated have a lower content of CFSE,
thus the upper-left panel shows T-cells that have reacted to the exogenous antigen. In the
two samples that replicated we had respectively 23.9 and 23.1% of cells that had divided,
that is an average of 23.5%, whichmeans that 100-23.5=76.5% of the cells did not replicate.
Cells went through 3 cell cycles in 3 days, so it can be assumed that cells went through one
cycle per day on average. At each cycle, cells which divide double, so the amount of cells
that are allo-reactive and start replicating at day 1 is 23.5%/23  3% of the final number.
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Figure 3 Cytofluorimeter analysis. Cells were analyzed for CD3 expression and CFSE incorporation. T-cells
are selected with CD3+ marker, on the y axis the group of cells above the horizontal line are CD3+. On the x
axis, the amount of CFSE indicates if cells replicated or not: for each cell division the amount of CFSE
incorporated in DNA is reduced by half. The upper left panel (red circle) contains T-cells which have replicated.
So, for every 100 cells in the final count, on day 1 we have 76.5 (cells that did not replicate)
+ 3 (cells that replicated), that is 79.5% of the final 100%. The global replication rate at
each rate was computed solving the following equation:
y3 = y0e−kmaxt (17)
where y0 is the total number of cells on day 0 (approximately 79) and y3 is the number
of total cells on day 3 (100), while kmax is the replication rate. Solving (17) with t = 3 we
obtain kmax=0.08 /day. kcacF = 0.08/10−5 l/g/day, which is 2.92 l/μg/year.
Model simulation
The model has been implemented in Matlab©2010b, and simulations are presented
showing the behavior of the several types of antigen and corresponding specific T-
cell populations after transplantation of a solid organ. Three scenarios are depicted,
corresponding respectively to the no-therapy, moderate therapy and maximal therapy sit-
uations. A time range from 35 to 60 years is shown, hypothesizing that transplantation
occurs at time 40 years.
In Figure 4 all antigen types, the corresponding T-cell dynamics, and drug concentra-
tions, are shown in the three therapy cases; subfigure 4.1 shows drug dynamics. In all
subfigures the solid line (–) represents the no-therapy case, the dashed line (- -) refers
to the moderate drug dose while the dotted line (..) refers to the high drug dose. Vari-
able concentration ranges, as will be explained in the discussion, are in agreement with
physiological limits.
Concentrations are assumed to be constant if no traumatic events happen during life.
As the allograft is introduced (taking, e.g., tτ = 40 years), all antigen types described
by the model (with the exception of the environmental antigen E) go from 0 to a high
level. In response, specific T-cell concentration also grows from a normal, low level to
a high one. The solid lines correspond to the no-therapy case: at the beginning antigen
concentrations are very high and so T-cells are quickly activated, causing antigen elim-
ination, which only partially regenerates (case of antigen S and its processed form, L).
After this first period, as T-cells react towards the graft to destroy it, antigen concentra-
tion (which is proportional to graft mass) decreases. Following antigen reduction, T-cell
concentrations are also reduced, but remain consistently higher than baseline (i.e. before
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Figure 4 Variables dynamics plots. For each variable three scenarios are shown: solid line represents no
therapy administration, the dashed line a middle immunosuppressant dose, and the dotted line a high dose.
In Figure 4.1 the pharmaceutical dynamics is shown, while in the other plots each antigen dynamics is in line
with the respective T-cell plot .
transplantation), as antigen from the organ is continuously produced and never vanishes
(T-lymphocytes Cl, Figure 4.6). If no therapy is applied, T-cell levels remain high and will
bring the organ to a minimal size (rejection and failure): as can be noticed, the continuous
line in the regenerating antigen graph (concentration of antigens S and L, Figure 4.4 and
4.5) is very low.
The dashed line represents the case in which administration of a moderate amount of
immunosuppressive drug (such as cyclosporine) takes place. We assume that the drug is
given simultaneously with the organ transplantation and that the patient is continuously
and constantly treated (subfigure 4.1). It should be noticed that, as the increase of T-cell
concentration is much lower, antigen level remains higher than the no-therapy case. This
indicates that the graft is not totally destroyed by the immune system.
If therapy is much stronger (dotted line), the graft normally survives. The problem is
that, with immunosuppression, T-cell levels fall well below normal. As T-cells are less
aggressively attacking the allograft, its regeneration allows the attainment of a constant,
sizable equilibrium level, but T-cells do not proliferate as much and are thereby less
effective not only towards the graft’s antigen, but also towards environmental antigens,
exposing the patient to opportunistic infections. In fact, while rejection is prevented,
patients might not be able to defend themselves from severe general infections. Any cho-
sen intensity of therapy represents a compromise between desirable graft tolerance (with
attending functional organ size) and dangerous lowering of general immune defenses.
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SubFigures 4.2 to 4.11 show the time course of specific antigens and their respective
T-cell dynamics. In subFigures 4.2 and 4.3, generic antigen and generic T-lymphocyte
concentrations are reported. If no therapy is administered, these dynamics are at equilib-
rium.With therapy, generic T-cell concentration decreases (depending on drug dose): this
indicates that immunosuppression is not specific in lowering T-cell expansion towards the
graft. Instead, it reduces proliferation of all T-cells and, as a consequence, environmental
antigen permanence levels in the body (E) increase.
In subfigures 4.4, 4.5 and 4.6, the concentrations of regenerating antigen in the non-
processed (S) and processed (L) forms, as well as T-cells that respond to it (Cl), are shown.
As seen before, in the absence of therapy, low antigen and high T-cell levels are reached
after transplantation, while with drug administration antigen and T-cell concentrations
are respectively higher and lower. This is the only case in which antigen never goes to zero
because it is produced from regenerating graft cells. Dynamics of directly presented, non-
regenerating antigen (U) and corresponding T-cells (Cu) are shown in subfigures 4.7 and
4.8: without therapy T-cells rapidly expand and consequently the antigen is rapidly elim-
inated, while, with therapy, the action of T-cells is less aggressive on this type of antigen,
which will eventually be eliminated because it does not regenerate. The non-regenerating
and indirectly presented antigen (subFigures 4.9 and 4.10) has to be processed: there is a
delay in the increase of Z, which depends on non-processed antigen (Y ) dynamics. The
unprocessed antigen rapidly grows and rapidly vanishes as it is processed to the indirectly
presented form and is no longer produced (because it derives fromAPCs not reproducing
in the graft).
In subfigure 4.11 the dynamics of specific T-cells primed for antigen Y and Z is shown.
In this case as well, as drug dosages increase, T-cell concentrations decrease and antigen
levels rise.
From the graphs shown it is evident that is not easy to find the right drug dosage. In
fact, it can be seen that when the dose is moderate T-cell levels are adequate but the graft
tissue size is too small, while, as drug concentrations increase, T-lymphocyte levels are
not sufficient to defend the patient from infections. The perfect situation would be to find
a therapy level, which is effective in saving the graft from rejection, but does not unduly
expose the individual to infections.
Effect of immunosuppression on T-cell reaction towards infection
In order to explore the predictive ability of the model, a simulation of an infection occur-
ring two years after transplantation has been performed: the environmental antigen E and
its specific T-cell population are shown in Figure 5. It is clear that, if the patient is not
under treatment with the immunopuppressor (solid line) the immune system reacts nor-
mally (big increase in T-lymphocyte concentration) and the antigen is quickly brought
back to equilibrium levels. If the subject is immunosuppressed, T-cell population growth
is inhibited in a drug-dosage-dependent fashion, and the patient is not able to fight the
infection (elevated E antigen levels maintained for a long time).
Balance between organ survival and immunosuppression
As will be discussed in the Appendix, the subsystem S, L and Cl has two equilibrium
points. One is provided by the elementary triple S = 0, L = 0, Cl = kc/kxc, correspond-
ing to a situation of no antigen S, which may refer to the pre-transplantation case, when
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Figure 5 Environmental antigen and lymphocytes reaction to infection with different drug dosages.
Solid line, no immunosuppression; dashed line, middle dose; dotted line, high dose.
the patient has no actual exogenous organ mass. According to a proper setting of the
model parameters (see the Appendix for more details), this equilibrium point is shown
to be stable with respect to perturbations of L and Cl, and to be unstable with respect to
perturbations of S. On the other hand, the other, asymptotically stable equilibrium point
corresponds to a non-elementary solution for the three state variables and is eventually
reached after transplantation, when antigen and T-cells dynamics, under a certain drug
dose, are balanced. Let us denote by S¯ the value of S at the stable equilibrium that is even-
tually reached after transplantation, which represents the carrying capacity for antigen
concentration (which we assume proportional to organ mass), as explained in subsection
3.2. A simulation is performed to show how S¯ changes in relation to varying immuno-
suppressant concentrations. The plot in Figure 6 shows how the value of S¯ varies with
increasing drug doses: at F equal 0, S¯ has a positive (non zero) value, which is physio-
logically plausible as the antigen would not be completely eliminated without drug, but
its concentration would be low. As drug concentrations increase, S¯ increases following a
saturation curve: at high drug levels, when lymphocytes are inhibited, the antigen equi-
librium approximates its maximum level. Similar diagrams are reported in Figures 7, 8, 9,
10 (see Appendix).
Hypothetical cyclical therapy
An additional simulation was performed to test the effect of a hypothetical “intermittent”
therapy. The aim was to investigate the physiological response in the case of a cyclical
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Figure 6 S¯ versus F . With increasing drug dose (x axis) the S carrying capacity, representing organ
regeneration rate, increases and shows a saturation curve.
administration of immunosuppressant. The period of interruption equals the period
of treatment, and the given dose is the same in each treatment period. A comparison
between continuous and cyclical therapies is shown in Figure 11. The time interval
applied in the simulation shown is one year; several other time intervals were tested
(1 week, 2, 3, 4, 6 months, 2 years) and results were similar (results not shown). As shown
in Figure 11.1, the immunosuppressant is given at one year intervals. The red line repre-
sents the continuous therapy (low dose), while the blue and green lines the intermittent
therapies (low and high doses). In Figures 11.2 and 11.3 the effect of the three therapy
schemes on the environmental antigen (E) and the respective T-cells (Ce) are shown.
Figure 7 Bifurcation diagrams of the allograft regenerating antigen indirectly presented subsystem.
The bifurcation diagrams refer to the non elementary equilibrium points of subsystem (19), according to
varying amount of drug F (the bifurcation parameter) from 0 to 350 ng/ml.
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Figure 8 Bifurcation diagram for S, the antigen produced by graft cells, non-processed form. The
bifurcation diagrams refer to the equilibrium points of S in (19), according to varying amount of drug F (the
bifurcation parameter) from 0 to 350 ng/ml. The continuous line indicates asymptotically stability, the dashed
line indicates instability.
Figures 11.4, 11.5 and 11.6 show the dynamics of antigen S and its processed form
L - representing the organ mass - and the corresponding T-lymphocytes (Cl). The low
intermittent dosage is less aggressive towards T-lymphocytes and, correspondingly, the
subject is better protected against environmental antigens, but the organ is not protected
from rejection as much as with the continuous dosage. The high intermittent dosage is
less effective than the low continuous one, T-cells are not sufficiently inhibited and the
graft antigen level is low.
Sensitivity analysis
Three variables have been identified as the most important ones to describe rejection
and immunosuppression in a clinical setting: S and T , representing the organ mass
(non-processed and processed form of the organ antigen) and Ce, the T-cells specific for
Figure 9 Bifurcation diagram for L, the antigen produced by graft cells, processed form. The
bifurcation diagrams refer to the equilibrium points of L in (19), according to varying amount of drug F (the
bifurcation parameter) from 0 to 350 ng/ml. The continuous line indicates asymptotically stability, the dashed
line indicates instability.
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Figure 10 Bifurcation diagram forCl , T-cells activated from the processed antigen. The bifurcation
diagrams refer to the equilibrium points of Cl in (19), according to varying amount of drug F (the bifurcation
parameter) from 0 to 350 ng/ml. The continuous line indicates asymptotically stability, the dashed line
indicates instability.
the environmental antigen. Sensitivity analysis of these variables at 1 year and at 10 years
after transplantation (t =41 and t =50) has been performed (tornado plots are shown in
Figure 12).
Ce at t =41 and Ce at t =50 plots are reported in Figures 12.1 and 12.2, respectively.
The first observation is that the parameters affecting the two targets are the same, but in
a different priority order. Also, at one year after transplantation, the variable Ce is gener-
ally more sensitive to parameter variations compared to the (near) equilibrium state at 10
Figure 11 Intermittent therapy simulation. Red line, continuous high drug dosage; green line, high dosage
cyclical therapy (every year); blue line, low dosage cyclical therapy (every year). Environmental antigen (E) and
regenerating organ antigens (S and L) are represented, with the corresponding T-cell dynamics (Ce and Cl).
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Figure 12 Sensitivity analysis. Tornado plots for selected variables (Ce , S and L) at time 41 and 50 years. The
variable percent variation for each parameter 1% increase is shown. Parameters are ordered on the y axis
from the most (top) to the less (bottom) influent one.
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years post-transplantation. The kxc parameter is most influent on both variables: it rep-
resents physiological T-cell elimination, due to natural apoptosis. It is noticeable that the
other elimination rate, kxce, which is the elimination due to T-cell interaction with the
antigen, is much lower. This is understandable, since kxc represents a general mechanism
that involves all cells while kxce only applies to cells in contact with their specific antigen.
Another aspect worth noticing is that the rates which directly influence the environmen-
tal antigen (E), kxe, kxec and ke, are important at t =41 but negligible at t =50 (variation
0.05% or less).
Figures 12.3 and 12.4 show tornado plots for S at t =41 and S at t =50. The parameters,
to which the two targets for the S antigen are most sensitive, are broadly the same. The
major difference is in antigen regeneration. For both t =41 and t =50 variations in S∗ are
relevant, whereas variations in ks only impact model-predicted S levels at 10 years post-
transplantation, likely due to an accumulated effect of the small rate change. Besides the
above described parameters, which regulate the S regeneration term, the parameters to
which the variable S is most sensitive are the ones which regulate drug action on T-cells
(kxf inverse correlation with S increase, and lambda direct correlation with S increase)
and the T-cell clonal expansion rate (kcacF ). Also the transfer rate from S to L antigen
forms (kls) is a relevant parameter. It must be kept in mind that S is the non-processed
form of the regenerating antigen, and it does not directly activate T-lymphocytes, while
it is directly eliminated by them. In fact, the parameters governing the variation of L, the
antigen processed form, are somewhat influent on both targets.
Tornado plots for L at t =41 and L at t =50 are reported in Figures 12.5 and 12.6,
respectively. The processed form of the regenerating antigen is mostly affected by varia-
tions of the parameters lambda, kcacF and kxf , as described above for the non-processed
form, while it is not much affected by those parameters which regulate the processed form
of S (S∗ and ks), both at time 41 and 50. One interesting observation concerns the sensi-
tivity to the parameter kls, the transfer rate from the S to the L form: one would expect an
increase in this parameter to result in an increase in the target, while at t =41 there is -
1% variation in L. This is probably due to the fact that, in the moment in which the T-cell
expansion stimulation is most effective, an increase in processing rate leads to an increase
in the form available to activate the cells, which results in a faster clonal expansion and
thus lower antigen level. At time 50, instead, the effect is almost negligible, because we
are at an equilibrium situation.
As a general comment to the sensitivity analysis it is evident that the parameter kcacF
is surely relevant. Accurately assessing the value of the kcacF parameter (derived from
the MLR experiment) seems important for a correct quantitative prediction of the time
course of the lymphocyte populations, as could naturally be expected. This point should
be kept in mind upon applying the model in a clinical context, possibly predicting an
individual patient’s post-transplantation course.
Discussion
Mathematical models are increasingly used in biology and clinical medicine to express
concise, mechanistic descriptions of ongoing phenomena. The possibility of repre-
senting a pathophysiological process by means of a mathematical model allows the
investigator to formalize beliefs, compare interpretations and simulate hypothetical sce-
narios of interest. Mathematical models have in particular already been introduced
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into several areas of immunology [3-8]. So far, however, no mathematical model has
yet been presented describing allograft rejection in order to support the evaluation
of therapies.
The clinical problem, which characterizes the management of the transplanted patient,
is the difficult adjustment of immunosuppressive therapy, walking the fine line between
under-suppression, with ensuing organ rejection, and over-suppression, with the danger
of potentially lethal opportunistic infections. While a wide spectrum of active pharma-
cological agents are now available to the transplantation specialist, their mechanism of
action is often incompletely understood and their precise effect on the complex balance of
immune system competence is not quantitatively determined. Therapy therefore follows
rule-of-thumb principles, intensivemonitoring of potential damage indicators (like serum
creatinine for kidney, hepatic enzymes for liver transplantation), meticulous monitoring
of plasma drug levels. The relationship between the time courses of drug effect, T-cell
cycle and organ damage is however a matter of guesswork, only partially mitigated by the
relatively precise knowledge of the pharmacokinetics of the immunosuppressive drugs
themselves. In fact, what pharmacological information is currently offered to clinicians
consists largely of single-drug pharmacokinetics parameters. Recent experiences have
indeed suggested that the possibility of studying drug pharmacokinetics and pharmaco-
dynamics through modeling techniques (in silico) may greatly reduce the need for animal
and cellular models [19], as well as the discomfort and risks associated with extensive
human experimentation. In order to work in concrete, however, the modeling approach
requires a tight interconnection of mathematical constructs and physiological knowledge.
The model presented here describes established physiology mechanisms, whose out-
comes, however, are not directly detectable with clinical measurements. Specific T-
lymphocyte clonal expansion after foreign antigen contact, which is known to be the first
step of the cascade leading to organ rejection [11], is not directly measured in clinical
practice [20].
Variables concentration ranges, reported in the plots, were obtained setting the param-
eters in order to have a physiological reproduction of rejection, with the exception of
the experimentally derived parameter kcacF which was maintained constant. It is worth
noticing that the concentration ranges reflect physiological values. Regarding T-cell con-
centrations, it has been reported that the physiological range for T-cells (CD4+ and
CD8+) is 750-3600 cells/μl [17], which is of course variable depending on the subject
and on the situation (immune status, period of the year, general physical conditions etc.).
Experiments reported in the literature give ranges of approximately 1200-1700 cells/μl
[21] in physiological conditions. In the plots, if we sum the concentrations of all anti-
gen types before transplantation, we have a value of about 2 ∗ 103 cells/μl. As regards
drug concentrations, the reported values for cyclosporine treatment are 150-350 ng/ml,
depending on the period following transplantation [22] which is also in agreement with
our simulation: in the plot, the hypothesized drug concentrations are approximately 100
(low dose) and 350 (high dose) ng/ml. Regarding antigen concentrations, the situation is
more complicated, since values for it cannot be found (as far as we know) in the literature.
However, while still remaining consistent with cell-surface molecule densities as they are
generally known, we may simply assume arbitrary concentrations proportional to organ
mass: a rapid decrease in this arbitrary antigen concentration would signal an ongoing
rejection process.
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The proposed model describes the pre-transplantation equilibrium state, character-
ized by constant environmental antigen and T-cells level, which is dramatically perturbed
by the entry of a large amount of alloantigens. Regenerating antigen determines the
continuation over time of the immune system activation, leading to possible chronic
rejection. The administration of therapy limits the immunological aggression towards the
organ and the natural ability of the allograft to reproduce makes it so that an equilibrium
is attained at a non-zero level of remaining allograft tissue. This is potentially the most
useful area of application of future versions of the present model, which will incorporate,
besides a general biological description of the immune response, also a precise quantifica-
tion of the applicable pharmacokinetics (possibly depending on the patient or on patient
subgroups).
Immunosuppressive therapy is very invasive and the substantial risks of potentially
severe side effects have been widely discussed [23,24]. Models for therapy improvement
(e.g. drug dosage) have been proposed, so far only considering single aspects of the ther-
apy (e.g. plasma drug concentrations) or focusing on the action of a single specific drug
[25,26]. Themodel presented here has instead the aim of framing drug kinetics and effects
within a simplified representation of the relevant immune system biology. The somewhat
empirical therapy adjustments in clinical practice, which at present are based on organ
function damage indicators and drug level monitoring, may therefore be complemented,
using a model similar to the one presented here, by a quantitative systemic assessment
of the likely impact of posology alterations, considering therapy effects in the context of
patient individual characteristics and immune system status.
The study of the present model prompts, in fact, some interesting considerations.
One aspect worth noticing, which in clinical practice is subject to iterative attempts, is
therapy adjustment. The model explicitly shows that a constant dosage of one immuno-
suppressant is never satisfactory since no good compromise can be achieved in this way
between organ survival and acceptable patient immune defenses. Even if this fact is widely
appreciated among clinicians (and in fact therapy is adjusted testing it directly on the
patient), there has never been, in our knowledge, a direct demonstration of it [22]. With
the present model we have attempted to follow in detail the fate of several among the
most meaningful cellular and chemical species involved in the immune response to organ
transplantation. In so doing, we attempted a mechanistic description of those factors pro-
moting species accumulation and decay, thereby falling naturally into the framework of
mass action kinetics.
In the present work, a simulation where intermittent therapies were tested (see
Figure 11) indicates that this kind of intermittent treatment would not be effective. In fact,
even if the intermittent dosage is almost three times the continuous one, therapy is more
effective with the latter.
In the model, the dynamics of the several types of antigen and lymphocytes are coupled
through the effects of immunosuppressive therapy, acting equally on all types of T-cells.
Decoupling of the several state variables, linked only by the drug effect, is actually a rel-
evant feature of the model: therapy acts on the whole immune system; if it could act
only on those cells which specifically clear graft antigens, immunosuppression would not
affect individual protection against infections. This aspect also underlies how important
it would be to have more specific data from transplanted patients. Also, data availability
would definitely be useful for parameter identification.
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Once a robust biological model is in place, it becomes relatively easy to incorporate
the effect of different drugs. It will therefore be possible to express the suppression of
clonal expansion, a greater mortality of T-lymphocytes, or even a generalized action in
suppressing the inflammatory response (as may happen when administering corticos-
teroids). The problem here will not be as much in introducing the specific actions of
the array of available therapy schemes, commonly used in clinical practice, but rather in
representing with some degree of accuracy those side effects, which make it undesirable
to simply increase without bounds the dosage of immediately useful agents. It will become
possible, in this way, to support the decision-making of the attending physician or sur-
geon, who has to choose a reasonable compromise between immediate therapeutic effect
and long-term complications.
The model presented in this work has been developed with the aim of allowing
the eventual representation of different mechanisms of action, hence of the effects, of
different classes of immunosuppressive drugs. Mechanisms can differ either from the
molecular or the cellular viewpoint. There are different steps, along the pathway of
T-lymphocyte activation, at which drugs can act (resting state, early activation, late acti-
vation and proliferation). Polyclonal anti-lymphocyte antibodies act at the resting state.
Calcineurine inhibitors (cyclosporine, tacrolimus) act in the early activation pathway,
so they have the same inhibition mechanism from the cellular viewpoint. However,
cyclosporine and tacrolimus have different chemical structure, and act with different
mechanisms at the molecular level. It has in fact been reported that tacrolimus is
more effective than cyclosporine, it is used in smaller concentrations, and there are
differences in their side effects [27,28]. Monoclonal antibodies and rapamycin (TOR)
inhibitors act in the late activation step. Antiproliferative drugs (azathioprine and
mycophenolate acid) act on the last step of the activation pathway. Corticosteroids
have a very different mechanism of action in that they do not inhibit T-cell pro-
duction, but they act non-specifically on the inflammatory process, preventing organ
failure without directly acting on T-cell dynamics [1]. The current model can also be
modified by explicitly representing different steps of the activation pathway as well
as focalizing on molecular aspects for a better description of different mechanisms
of action.
In this representation, some simplifications have been deliberately introduced. Among
these, no discrimination has been made concerning the different T-cell types: T-
lymphocytes can be either naive or activated; once activated, they differentiate into cells
with specific roles (mainly helper and cytotoxic); in the presentmodel, however, the global
class of T-cells is considered, representing the response to transplantation of the immune
system as a whole. The consideration of different cellular types, besides T-Lymphocytes of
the CD4 and CD8 classes, would in fact be helpful in refining the description of the chain
of events involved in the inflammatory response. Other cells of the immune system (e.g.
antigen presenting cells, B-lymphocytes, macrophages etc.) as well as cytokines (respon-
sible of cell proliferation, signaling and recruiting inflammation agents) are also involved
in the rejection mechanisms. In the present work the need to limit model complexity has
prompted the decision of representing only the cellular compartment (T-lymphocytes),
most representative of solid organ rejection reaction, which directly increases in response
to incoming antigen and triggers the rejection response.While the inflammatory response
is not followed in detail, a measure of the inflammatory damage to the organ is however
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represented by the amount of circulating L antigen, assumed to be proportional to the
tissue mass of living allograft.
Another simplification consists in not representing explicitly the increased overall
T-cell production occurring in the presence of inflammation. When an inflammatory
process is ongoing (e.g. during rejection) lymphoid organs are stimulated to non-
specifically increase cell production. These mechanisms are poorly understood and the
actual increase in competent T-cells may not be so high as to substantially modify the
response: for this reason, a constant T-cell production was assumed (kc).
The main limitations of the current model invest both the detail of therapeutic manip-
ulations it describes and the plausibility of the represented biology. While the model, as
discussed above, can be easily and naturally extended to account for more than the sin-
gle pharmaceutical agent (F) incorporated so far, there are in fact important aspects of
the immunological response to transplantation which have not yet been tackled. One
such is the description of the Graft versus Host Response, which is of great importance
in explaining the events following transplantation of lymphoid tissue (like bone mar-
row transplants), particularly after massive immunosuppression of the recipient before
the operation: for this reason, the present model should be considered appropriate only
for solid organ transplants (liver, kidney, pancreas, heart). Another area where greater
biological detail would be useful is that of the description of the chain of events in the
inflammatory process which underlie the clinical features of chronic rejection. While
within the framework of the present model no distinction has been made between acute
(or indeed hyperacute) and chronic rejection mechanisms, factors leading to the different
types of rejection may be different, and may be the object of one type of model refine-
ment. In particular, while it is well known that acute rejection is mediated by CD4+ and
CD8+ T-lymphocytes stimulated from exogenous MHC, mechanisms leading to chronic
rejection are still not completely clear, and the latter is now the most common reason of
graft loss from the recipient.
While the model as reported does offer useful insights in the reciprocal variations of
antigen and immune cell species during a generic, hypothetical solid organ transplanta-
tion, model parameter estimation has not been carried out and no quantitative prediction
can be strictly constructed, not to mention the assessment of prediction uncertainty.
Indicative parameter values for the processesmodeled are difficult to find in the literature.
For this reason, the main criterion followed for parameter calibration was the production
of relative time-courses of relevant state variables, which appeared consistent with clinical
experience to the medical doctors among the authors, while remaining within a broadly
acceptable range of magnitude. A priori identifiability analysis of the model has not been
performed, and no data fitting has allowed us to assess a posteriori regions of confidence
on parameter values. As a consequence, themodel identifiability issue remains completely
open.
Conclusion
The graphs, reporting the time course of the different types of antigen and correspond-
ing T-cell populations, show that the model captures well the clinically expected behavior
of the transplanted organ mass and of the immune system reaction, under the three
scenarios of no therapy, moderate therapy and aggressive therapy. From the graphs it
is evident that is not easy to find the right drug dosage. It can be seen that when the
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drug dose is moderate T-cell levels are adequate to prevent opportunistic infections,
but the L-antigen level, corresponding to the viable graft tissue, is rather low. Con-
versely, at a drug concentration effective in maintaining the entire transplanted tissue
mass, the T-cell population is suppressed excessively and the risk of complications would
appear to become substantial. The model therefore predicts that single drug therapy
is likely to be inadequate to safely prevent graft rejection, in accord with the clinical
experience so far accumulated. A perfect situation might not exist, but the theoretical
exploration of drug combinations and of non-constant therapy schemes could be one
way to obtain useful indications for the biological experimentation of novel therapeutic
protocols.
The present work proposes then a first mathematical model of the cellular immune
response to solid organ transplantation, addressing both acute and chronic rejection. The
model’s mathematical behavior is broadly consistent with known physiology and long-
term variations in immune status and allograft survival. The model can be tailored to
address specific organ transplantation situations, may be naturally adapted to the rep-
resentation of different therapeutic regimens and may offer useful indications for the
optimization of therapy protocols in the transplanted patient.
Appendix: Qualitative behavior of the solutions
From a mathematical point of view, the whole system (1-10) may be split into the four
independent subsystems composing it, namely:
• the environmental antigen subsystem:
dE
dt = ke − kxecCeE − kxeE
dCe
dt = kc +
(
kcac(F) − kxce
)
ECe − kxcCe
(18)
• the allograft regenerating antigen indirectly presented subsystem:
dS
dt = ksτ + ksS − ks S
2
S∗ − kxscClS
dL
dt = klsS − kxlcClL − kxlL
dCl
dt = kc +
(
kcac(F) − kxcl
)
LCl − kxcsSCl − kxcCl
(19)
• the allograft non regenerating antigen directly presented subsystem:
dU
dt = kuτ − kxucCuU − kxuU
dCu
dt = kc +
(
kcac(F) − kxcu
)
UCu − kxcCu
(20)
• the allograft non regenerating antigen indirectly presented subsystem:
dY
dt = kyτ − kxycCzY − kxyY
dZ
dt = −kxzcCzZ − kxzZ + kzyY
dCz
dt = kc +
(
kcac(F) − kxcz
)
ZCz − kxcCz − kxcyYCz
(21)
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Each subsystem is driven by the common input given by the drug concentration F,
which evolves according to a step-wise trajectory:
F(t) =
⎧⎨
⎩
0, t < tτ
F¯ = κfkxf , t ≥ tτ
kcac(F) =
⎧⎨
⎩
kcacF , t < tτ
kcacFe−λF¯ , t ≥ tτ
(22)
Lemma. Each state component of the four subsystems endowed with a physiological
initial condition (i.e. all positive components), admits non-negative evolutions, ∀t ≥ 0.
Proof. Consider subsystem (18) and E(0) > 0. Due to the continuity of both E(t) and
dE/dt, the solution E(t) would become negative if there existed a time instant t¯ > 0 such
that E(t¯) = 0 and dEdt
∣∣∣
t=t¯ < 0, which is a contradiction because:
dE
dt
∣∣∣∣
t=t¯
= ke − kxecCe(t¯)E(t¯) − kxeE(t¯) = ke > 0. (23)
According to the same reasoning, it also readily appears that Ce(t) never vanishes. The
same approach can be repeated for the other three subsystems, since the delta-Dirac
functions simply model a positive instantaneous increase occurring at the time tτ of
transplantation.•
Lemma. As far as the environmental antigen subsystem (18) is concerned, there exists a
unique positive, locally asymptotically stable equilibrium point.
Proof. The equilibrium points of (18) satisfy the following algebraic equations:
ke = kxecCeE + kxeE
kc +
(
kcac(F) − kxce
)
ECe = kxcCe
(24)
from which it follows that the steady state of Ce satisfies the following second order
equation:
kxeckxcC2e +
(
kxekxc − kxeckc − ke
(
kcac(F) − kxce
))
Ce − kxekc = 0 (25)
Since the second- and zero-order coefficients are positive and negative respectively, both
solutions are real: one positive, the other negative, regardless to the sign of the first-order
coefficient (see, e.g., [29]). Thus we have a unique positive solution for Ce. As a matter of
fact, by substituting the positive solution into the first equation of (24) we have a unique
positive solution also for E:
E = kekxecCe + kxe > 0. (26)
As for the local stability analysis, we compute the Jacobian matrix:
Je =
⎡
⎣ −kxecCe − kxe −kxecE(
kcac(F) − kxce
)
Ce
(
kcac(F) − kxce
)
E − kxc
⎤
⎦ , (27)
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from which the characteristic polynomial is:
de(λ) =λ2 +
(
kxecCe + kxe −
(
kcac(F) − kxce
)
E + kxc
)
λ
+
(
kxc −
(
kcac(F) − kxce
)
E
)
kxe + kxckxecCe
=λ2 + (kxecCe + kxe + kc/Ce)λ + kxekc/Ce + kxckxecCe
(28)
Since all the coefficients are positive, the roots have negative real part [29], which means
local asymptotic stability of the equilibrium point. •
Remark. If we interpret the positive solution of (25) as a function of the drug F¯ adminis-
tered after transplantation it happens that, by increasing F¯ the corresponding equilibrium
for Ce reduces its value since the first order coefficient increases, keeping unchanged the
second- and zero-order terms. And, as a matter of fact, the corresponding equilibrium of
E increases its value. These equilibria are drawn in Figure 13: increasing values of F go
from the bottom right corner, corresponding to the pre-transplantation case F = 0, to the
upper left.
Lemma. The allograft antigen subsystem (19) admits an elementary equilibrium point
(S = 0, L = 0,Cl = kc/kxc), which is locally asymptotically stable if:
kskxc < kxsckc. (29)
Proof. The existence of the equilibrium point (S = 0, L = 0, Cl = kc/kxc) comes out by
ready computation. In order to investigate the local stability, compute the Jacobian matrix
and evaluate it at the equilibrium point:
Jl =
⎡
⎢⎢⎢⎣
ks − kxsckc/kxc 0 0
kls −kxlckc/kxc − kxl 0
−kxcskc/kxc
(
kcac(F) − kxcl
)
kc/kxc −kxc
⎤
⎥⎥⎥⎦ . (30)
Figure 13 Equilibrium points of the environmental antigen subsystem. The equilibrium points of
subsystem (18) are drawn on the (E, Ce) phase plane, according to varying amount of the drug F from 0 to
350 ng/ml.
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It clearly comes that the eigenvalues of Jl are the elements of the diagonal: therefore, the
equilibrium point is locally asymptotically stable if condition (29) is satisfied, since in that
case all the eigenvalues of the Jacobian matrix are negative real. •
Remark. It is reasonable to assume, from a physiological point of view, that the stability
condition (29) is not satisfied. In this case, according to the structure of the Jacobian
matrix, it happens that perturbations of the type (S = 0, L = L,Cl = kc/kxc + Cl ) allow
a trajectory definitely convergent to the equilibrium (S = 0, L = 0,Cl = kc/kxc), if L, Cl
are small enough. On the other hand, for any arbitrarily small S > 0, any perturbation of
the type (S = S, L = 0,Cl = kc/kxc) will make the trajectory diverge from equilibrium.
Indeed, simulations have been carried out by setting the model parameters in order not
to have inequality (29) satisfied (see Table 2).
The investigation for other equilibrium points of subsystem (29) requires the computa-
tion of the solutions of the following nonlinear algebraic system:
ks = ks SS∗ + kxscCl
klsS = kxlcClL + kxlL
kc +
(
kcac(F) − kxcl
)
LCl = kxcsSCl + kxcCl
(31)
By making substitutions, the previous system becomes:
S = S∗(ks−kxscCl)ks
L = klsS∗(ks−kxscCl)ks(kxl+kxlcCl)
γ3C3l + γ2(F)C2l + γ2(F)Cl + γ3 = 0
(32)
where:
γ3 = kxcskxsckxlcS∗ > 0
γ2(F) = kxsckxlkxcsS∗ − klskxscS∗
(
kcac(F) − kxcl
)− kxcskskxlcS∗ − kxckskxlc
γ1(F) = kskckxlc + klsksS∗
(
kcac(F) − kxcl
)− kxcskskxlS∗ − kxckskxl
γ0 = kskckxl
(33)
A qualitative analysis would provide conditions too cumbersome to be easily treated,
therefore a numerical bifurcation analysis has been carried out, according to the set of
parameters reported in Table 2. The bifurcation parameter is the drug amount F.
It turns out that there exists a unique triple of real positive solutions (S, L,Cl) for system
(32), whose values are depicted in Figure 7 versus the drug concentration F. It has to be
stressed that this equilibrium point is locally asymptotically stable whatever the value of
F. Figures 8, 9, 10 refer to the bifurcation diagrams for S, L and Cl with respect to the drug
concentration F.
Lemma. There exists a unique nonnegative, locally asymptotically stable equilibrium
point (U = 0, Cu = kc/kxc) for the directly presented allograft antigen (20), and there
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exists a unique nonnegative, locally asymptotically stable equilibrium point (Y = 0,
Z = 0, Cz = kc/kxc) for the non-directly presented allograft antigen (21).
Proof. The proof comes from direct computation, following the same lines of the
previous Lemmas.•
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